(Q38062681)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23182627%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

title

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23182627%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

main subject

placebo

0 references

hepatocellular carcinoma

1 reference

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23182627%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Camillo Porta

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23182627%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Lorenza Rimassa

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23182627%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Nicola Personeni

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23182627%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Brian Schwartz

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23182627%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Armando Santoro

1

1 reference

ORCID Public Data File 2021

Hans Van Vlierberghe

7

object named as

Hans Van Vlierberghe

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23182627%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

author name string

Ivan Borbath

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23182627%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Bruno Daniele

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23182627%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Stefania Salvagni

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23182627%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Jean Luc Van Laethem

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23182627%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Jörg Trojan

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23182627%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Frank T Kolligs

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23182627%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Alan Weiss

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23182627%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Steven Miles

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23182627%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Antonio Gasbarrini

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23182627%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Monica Lencioni

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23182627%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Luca Cicalese

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23182627%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Morris Sherman

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23182627%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Peter Buggisch

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23182627%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Roland M Schmid

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23182627%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Corrado Boni

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23182627%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Ziad Hassoun

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23182627%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Giovanni Abbadessa

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23182627%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Reinhard Von Roemeling

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23182627%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Maria E Lamar

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23182627%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Yinpu Chen

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23182627%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Cesare Gridelli

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23182627%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

publication date

20 November 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23182627%20AND%20SRC:MED&resulttype=core&format=json

Lancet Oncology Commission

18 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23182627%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23182627%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23182627%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

page(s)

55-63

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23182627%20AND%20SRC:MED&resulttype=core&format=json

Nonsurgical treatment of hepatocellular carcinoma

18 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970490-4

7 January 2021

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970490-4

7 January 2021

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970490-4

7 January 2021

Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970490-4

7 January 2021

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970490-4

7 January 2021

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970490-4

7 January 2021

The present and the future landscape of treatment of advanced hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970490-4

7 January 2021

Molecularly targeted therapy for advanced hepatocellular carcinoma in 2012: current status and future perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970490-4

7 January 2021

Targeting the HGF/Met signaling pathway in cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970490-4

7 January 2021

Targeting MET in cancer: rationale and progress

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970490-4

7 January 2021

ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970490-4

7 January 2021

Breast cancer-derived bone metastasis can be effectively reduced through specific c-MET inhibitor tivantinib (ARQ 197) and shRNA c-MET knockdown

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970490-4

7 January 2021

Phase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic Studies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970490-4

7 January 2021

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970490-4

7 January 2021

Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970490-4

7 January 2021

A phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970490-4

7 January 2021